Drug Trial Radar · NCT03602079
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Last checked: Nov 19, 2026Latest source record: Aug 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Jul 16, 2018
Primary completion
Jan 12, 2022
Study completion Jan 12, 2022
Sponsor
- Lead sponsor
- Klus Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.
Conditions
- HER2-positive Breast Cancer
- HER2 Gene Mutation
- HER-2 Gene Amplification
- HER2 Positive Gastric Cancer
- Salivary Gland Cancer
- Salivary Gland Tumor
- Salivary Gland Carcinoma
- Salivary Gland Neoplasms
- Lung Cancer
- Colo-rectal Cancer
- Rare Diseases
- Solid Tumor
- Recurrent Gastric Cancer
- Recurrent Colon Cancer
- Recurrent Breast Cancer
- Head and Neck Cancer
- Head and Neck Carcinoma
- Bladder Cancer
- Cervical Cancer
- Liver Cancer
- Bile Duct Cancer
- Urologic Cancer
- Pancreatic Cancer
- Prostate Cancer
- Recurrent Prostate Cancer
- Rectal Cancer
- Recurrent Ovarian Carcinoma
- Recurrent Renal Cell Cancer
- Rectal Cancer Stage II
- Rectal Cancer Stage I
- Rectal Cancer Stage III
- Skin Cancer
- Mouth Cancer
- Lip Cancer Stage I
- Tongue Cancer
- Breast Neoplasm Malignant Primary
- Larynx Cancer
- Tonsil Cancer
- Palate Cancer
- Mucoepidermoid Carcinoma
- Primary Peritoneal Carcinoma
- Mucinous Adenocarcinoma Gastric
- Mucinous Breast Cancer Recurrent
- Cholangiocarcinoma
Interventions
A166Drug
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Maximum Tolerated DoseTime frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Florida Cancer Specialists & Research Institute
Sarasota, Florida
Beth Israel Deaconess Medical Center Cancer Center
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Clinical Research Alliance, Inc.
Lake Success, New York
Stephenson Cancer Center
Oklahoma City, Oklahoma
Providence Cancer Institute
Portland, Oregon
Mary Crowley Cancer Research Centers - Medical City
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, Texas
Virginia Cancer Specialist
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.